Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Bayer AG : Expansion of germplasm-pool for wheat:

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/14/2011 | 11:30am CET
Bayer CropScience acquires access to wheat germplasm from leading Romanian agricultural research institution
Monheim, October 14, 2011 – Bayer CropScience and the National Agricultural Research and Development Institute (NARDI) in Fundulea/Romania have signed a license agreement. With this agreement, Bayer gains access to winter wheat germplasm of NARDI, the leading Romanian agricultural research institution. Its germplasm pool is renowned world-wide for its winter hardiness, high tolerance against drought, broad disease resistance and good milling and baking quality. Financial details were not disclosed.
“Improving the productivity of wheat cropping will be critical to achieving global food security. Our customers have turned to us to find new ways to help them, we have listened and are building a world-class research platform for wheat genetics. Our agreement with NARDI is another key building block in this strategy“, said Hartmut van Lengerich, Head of Cereals and Fungicides at Bayer CropScience. “To speed up development of new varieties, we have already entered into collaborations with the best partners in wheat research and breeding, reaching from Australia to Israel, France and Ukraine to the United States – and now Romania.”
“Producing enough wheat to feed the world is an immense challenge and anyone willing to invest in the effort to meet this challenge is welcome”, said Marian Verzea, General Director of NARDI. “NARDI is proud that the wheat germplasm developed by its breeding program will be used to speed up genetic progress in breeding better wheat cultivars for other parts of the world, too.”
Key figures about wheat:
With about 25 percent of the global agricultural land under wheat cultivation, it is the largest cereal crop in terms of acreage and one of the world’s most important staple foods. Wheat is the second most-produced cereal crop after corn with more than 650 million tons produced every year. Wheat productivity is increasing at less than 1 percent annually, while the annual global demand is growing at approximately double that percentage. Main wheat producing regions are Australia, the Black Sea Region, China, the EU, India and North America.
About Bayer CropScience
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer CropScience, a subgroup of Bayer AG with annual sales of EUR 6.830 billion (2010), is one of the world’s leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and traits. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of 20,700 and is represented in more than 120 countries. This and further news is available at: www.press.bayercropscience.com.
About NARDI
NARDI Fundulea is recognized as the main agricultural research unit in Romania, due to the results obtained in breeding and crop management research & development regarding cereals, industrial and forage crops. Results of wheat breeding have a special place in NARDI’s research portfolio. NARDI’s twenty nine common wheat cultivars released since 1957 have had the largest share of the Romanian wheat seed market for more than 30 years, while nine NARDI wheat cultivars have been released in other countries, such as Canada, Argentina, Hungary, Turkey. Further information is available at: www.incda-fundulea.ro
Find more information at www.bayercropscience.com.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
12/14 BAYER : Studies from Bayer Update Current Data on Nerve Tissue Proteins (A tripa..
12/13 BAYER : rivaroxaban submitted to U.S. FDA for approval in patients with coronary..
12/13DJPLANT IMPACT : Needs Extra GBP7 Million Funding by April, Hands up 'For Sale' Si..
12/12 Monsanto offers cash to U.S. farmers who use controversial chemical
12/08 EU regulators to warn Bayer about Monsanto bid
12/08 BAYER : Preventive Maintenance & service solution on existing Bayer/Medrad and A..
12/08 BAYER : J-- Preventive Maintenance & service solution on existing Bayer/Medrad a..
12/08 'Right steps' point to a healthier China
12/07 BAYER : Research Conducted at Bayer Has Provided New Information about Atrial Fi..
12/07 BAYER : Findings from Bayer Has Provided New Data on Liver Cancer (Exposure-resp..
More news
News from SeekingAlpha
12/15 MY JOURNEY TO FINANCIAL INDEPENDENCE : 86-Stock November Portfolio Update - Buyi..
12/15 Nektar Therapeutics down 1% premarket after Bayer bails on agreement to devel..
12/14 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 14, 2017
12/11 Buy Celgene And Regeneron On The Dips As Insiders Are Buying
12/08 BLOOMBERG : Bayer to face EU objections to Monsanto deal in coming days
Financials (€)
Sales 2017 35 679 M
EBIT 2017 7 597 M
Net income 2017 6 179 M
Debt 2017 8 778 M
Yield 2017 2,46%
P/E ratio 2017 14,03
P/E ratio 2018 18,35
EV / Sales 2017 2,71x
EV / Sales 2018 2,48x
Capitalization 88 070 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 121 €
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER7.43%103 473
JOHNSON & JOHNSON23.65%382 722
PFIZER14.53%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.4.94%212 270
MERCK AND COMPANY-4.47%153 386